Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: This session will review reinsurance fundamentals, risk assessment techniques, optimization strategies, and regulatory considerations through case studies and best practices. Attendees will gain insights into enhancing capital management, risk mitigation, and improving operating results, utilizing practical insights from both reinsurers and direct experience. This presentation offers a valuable and practical opportunity to navigate the complexities of reinsurance, optimize transactions, and driving strategic growth in today's dynamic insurance landscape.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: This article highlights the findings of a recent SOA survey on accelerated underwriting (AU) practices, including the amount of AU business ceded, the results of three opinion questions, and an estimate of mortality slippage among AU programs.

Description: Description and welcome to the 2020 Canadian Reinsurance Conference including highlight of the key note speaker

Description: With more than 24 years of experience in the reinsurance market, Bruno Freire is the CEO and one of the co-founders of Austral Re, along with Vinci Partners, a private equity firm. Austral Re is a Brazilian- based multiline reinsurer which that writes business across Latin America. It has grown organically throughout the last 13 years, and had its credit rating upgraded to A- in 2023 by AM Best (it also has AAAbr from S&P). Before joining Austral, Bruno had been a reinsurance broker at Aon Re for more than 10 years, having witnessed the opening of the reinsurance market in Brazil. As we will be seen in his interview the following, he believes in a data driven analytic approach, client focused but with an underwriting mindset, as well as a strong support from actuaries and technology as key instruments to run a reinsurance company successfully.

Description: Artificial intelligence (AI) at the heart of new digital tools allows actuaries to extract structured data useful for creating more precise risk assessment models. This technology sits best alongside the expertise of insurance professionals who have years of experience in the industry. RGA’s partnership with DigitalOwl is an example of how AI combines with human knowledge for the best outcomes.

Description: Session 2B: Pharmacy Risk Mitigation - Pricing, Programs, Pools, and Performance Guarantees

Description: With coinsurance of an existing block of long-duration insurance contracts, there may be existing reinsurance that remains in force. The new coinsurance is typically net of such “inuring reinsurance.” In this article, we look at approaches that the new reinsurer might apply to account for the effects of inuring reinsurance.

Description: Come discuss how reinsurers can work side by side with insurer to better develop products, and lift in the areas that reinsurers have more experience, help matching products with distributions (or vice versa) and provide advanced technologies associated with tools and software. The speakers will also present Direct to Consumer plan from various points of view, i.e., distributors, carriers, and reinsurers. Some case studies will also be presented where traditional reinsurers and asset-intensive reinsurers helped insurers bring products to life.